LINESSA 21 TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DESOGESTREL; ETHINYL ESTRADIOL; DESOGESTREL; ETHINYL ESTRADIOL; DESOGESTREL; ETHINYL ESTRADIOL

Pieejams no:

ASPEN PHARMACARE CANADA INC.

ATĶ kods:

G03AB05

SNN (starptautisko nepatentēto nosaukumu):

DESOGESTREL AND ESTROGEN

Deva:

0.1MG; 0.025MG; 0.125MG; 0.025MG; 0.15MG; 0.025MG

Zāļu forma:

TABLET

Kompozīcija:

DESOGESTREL 0.1MG; ETHINYL ESTRADIOL 0.025MG; DESOGESTREL 0.125MG; ETHINYL ESTRADIOL 0.025MG; DESOGESTREL 0.15MG; ETHINYL ESTRADIOL 0.025MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

21

Receptes veids:

Prescription

Ārstniecības joma:

CONTRACEPTIVES

Produktu pārskats:

Active ingredient group (AIG) number: 0650285001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2018-02-01

Produkta apraksts

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
LINESSA
® 21 AND
PR
LINESSA
® 28
desogestrel and ethinyl estradiol tablets USP
0.100 mg, 0.025 mg
0.125 mg, 0.025 mg
0.150 mg, 0.025 mg
Oral Contraceptive
G03AB05
Aspen Pharmacare Canada Inc.
8 – 1155 North Service Road West
Oakville, ON
L6M 3E3
Date of Initial Approval:
June 13, 2006
Date of Preparation:
September 12, 2023
Trademarks are owned by or licensed to the Aspen Group of companies.
©
2023 Aspen Group of companies or its licensor. All rights reserved.
Submission Control No: 273119
_ _
LINESSA
®
21 and LINESSA
®
28 (desogestrel and ethinyl estradiol tablets)
© 2023 Aspen Group of companies or its licensor. All rights reserved.
_ _
_Page 2 of 72_
RECENT MAJOR LABEL CHANGES
Contraindications (2)
09/2023
Warnings and Precautions (7)
09/2023
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATION
.................................................................................
6
4.1
Dosing Considerations
........................................................................................